All patients
Age < 65y (younger) Age > 65y Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 1% stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mesothelioma (MS), immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 743, 2021 0.74 [0.60; 0.91]
DETERMINE, 2017 0.92 [0.76; 1.12]
0.83 [0.67 ; 1.02 ] CheckMate 743, 2021, DETERMINE, 2017 2 56% 571 low not evaluable progression or deaths (PFS)detailed results CheckMate 743, 2021 1.00 [0.82; 1.21]
DETERMINE, 2017 0.81 [0.67; 0.97]
0.90 [0.73 ; 1.10 ] CheckMate 743, 2021, DETERMINE, 2017 2 58% 1,176 low not evaluable DCRdetailed results CheckMate 743, 2021 0.57 [0.38; 0.87]
DETERMINE, 2017 1.39 [0.92; 2.09]
0.89 [0.37 ; 2.12 ] CheckMate 743, 2021, DETERMINE, 2017 2 89% 1,176 low not evaluable objective responses (ORR)detailed results CheckMate 743, 2021 0.88 [0.64; 1.22]
DETERMINE, 2017 4.35 [1.00; 19.05]
1.65 [0.36 ; 7.65 ] CheckMate 743, 2021, DETERMINE, 2017 2 77% 1,176 moderate not evaluable STRAE (any grade)detailed results CheckMate 743, 2021 0.92 [0.65; 1.31]
0.92 [0.65 ; 1.31 ] CheckMate 743, 2021 1 0% 584 NA not evaluable TRAE (grade 3-4)detailed results DETERMINE, 2017 1.74 [1.22; 2.47]
1.74 [1.22 ; 2.47 ] DETERMINE, 2017 1 0% 569 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 743, 2021 2.86 [0.30; 27.64]
DETERMINE, 2017 1.50 [0.76; 2.95]
1.58 [0.82 ; 3.03 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 743, 2021 1.59 [1.05; 2.41]
1.59 [1.05 ; 2.41 ] CheckMate 743, 2021 1 0% 584 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 743, 2021 2.21 [1.28; 3.81]
2.21 [1.28 ; 3.81 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 0.57 [0.19; 1.73]
0.56 [0.20 ; 1.61 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 743, 2021 7.66 [0.40; 145.59]
DETERMINE, 2017 3.00 [0.15; 60.20]
4.84 [0.59 ; 39.53 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
DETERMINE, 2017 0.99 [0.03; 29.79]
1.37 [0.12 ; 15.19 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.03 [0.00; 0.19]
DETERMINE, 2017 1.68 [0.46; 6.16]
0.23 [0.00 ; 13.19 ] CheckMate 743, 2021, DETERMINE, 2017 2 91% 1,153 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
DETERMINE, 2017 0.99 [0.03; 29.79]
1.37 [0.12 ; 15.19 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Arthritis TRAE (grade 3-4)detailed results CheckMate 743, 2021 3.81 [0.17; 84.75]
DETERMINE, 2017 0.99 [0.03; 29.79]
2.07 [0.21 ; 20.46 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.04 [0.00; 0.64]
DETERMINE, 2017 1.50 [0.40; 5.62]
0.30 [0.01 ; 10.72 ] CheckMate 743, 2021, DETERMINE, 2017 2 81% 1,153 low not evaluable Back pain (TRAE grade 3-4)detailed results DETERMINE, 2017 0.08 [0.00; 1.64]
0.08 [0.00 ; 1.64 ] DETERMINE, 2017 1 0% 569 NA not evaluable Chills TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 6.76 [0.83; 55.31]
DETERMINE, 2017 25.42 [1.54; 420.53]
10.88 [2.02 ; 58.51 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 0.25 [0.02; 2.74]
0.31 [0.04 ; 2.19 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Cough TRAE (grade 3-4)detailed results DETERMINE, 2017 0.25 [0.01; 7.42]
0.25 [0.01 ; 7.42 ] DETERMINE, 2017 1 0% 569 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.95 [0.13; 6.76]
DETERMINE, 2017 2.01 [0.42; 9.56]
1.50 [0.44 ; 5.10 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 743, 2021 4.86 [1.06; 22.39]
DETERMINE, 2017 33.86 [4.65; 246.49]
11.52 [1.74 ; 76.27 ] CheckMate 743, 2021, DETERMINE, 2017 2 57% 1,153 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.25 [0.01; 7.42]
0.25 [0.01 ; 7.42 ] DETERMINE, 2017 1 0% 569 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 0.58 [0.33; 1.02]
0.58 [0.33 ; 1.01 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Epistaxis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.56 [0.13; 2.38]
DETERMINE, 2017 0.49 [0.14; 1.72]
0.52 [0.20 ; 1.34 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.16 [0.01; 3.14]
0.16 [0.01 ; 3.14 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 3.81 [0.17; 84.75]
DETERMINE, 2017 0.99 [0.03; 29.79]
2.07 [0.21 ; 20.46 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results DETERMINE, 2017 3.00 [0.15; 60.20]
3.00 [0.15 ; 60.20 ] DETERMINE, 2017 1 0% 569 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.95 [0.02; 47.87]
DETERMINE, 2017 0.99 [0.03; 29.79]
0.97 [0.07 ; 12.71 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
5.73 [0.29 ; 114.85 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 743, 2021 9.61 [0.52; 176.72]
DETERMINE, 2017 1.75 [0.36; 8.53]
2.60 [0.64 ; 10.59 ] CheckMate 743, 2021, DETERMINE, 2017 2 1% 1,153 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 743, 2021 11.79 [1.52; 91.29]
DETERMINE, 2017 1.85 [0.51; 6.71]
3.91 [0.66 ; 23.24 ] CheckMate 743, 2021, DETERMINE, 2017 2 56% 1,153 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
DETERMINE, 2017 0.99 [0.03; 29.79]
2.66 [0.28 ; 25.23 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.24 [0.01; 5.24]
0.24 [0.01 ; 5.24 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Myalgia TRAE (grade 3-4)detailed results DETERMINE, 2017 1.99 [0.09; 44.45]
1.99 [0.09 ; 44.45 ] DETERMINE, 2017 1 0% 569 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
1.90 [0.06 ; 56.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Myositis TRAE (grade 3-4)detailed results CheckMate 743, 2021 3.81 [0.17; 84.75]
3.81 [0.17 ; 84.75 ] CheckMate 743, 2021 1 0% 584 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.13 [0.02; 1.08]
DETERMINE, 2017 2.00 [0.22; 18.02]
0.50 [0.04 ; 7.22 ] CheckMate 743, 2021, DETERMINE, 2017 2 67% 1,153 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.04 [0.01; 0.16]
DETERMINE, 2017 0.99 [0.18; 5.48]
0.19 [0.01 ; 4.62 ] CheckMate 743, 2021, DETERMINE, 2017 2 88% 1,153 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.09 [0.01; 1.71]
DETERMINE, 2017 0.25 [0.01; 7.42]
0.14 [0.02 ; 1.29 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Paraesthesia TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.03; 29.79]
0.99 [0.03 ; 29.79 ] DETERMINE, 2017 1 0% 569 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results DETERMINE, 2017 1.99 [0.09; 44.45]
1.99 [0.09 ; 44.45 ] DETERMINE, 2017 1 0% 569 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 0.89 [0.29; 2.70]
0.84 [0.29 ; 2.41 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 1.90 [0.06; 56.75]
DETERMINE, 2017 0.99 [0.03; 29.79]
1.37 [0.12 ; 15.19 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
DETERMINE, 2017 3.00 [0.15; 60.20]
4.15 [0.50 ; 34.55 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 3.00 [0.15; 60.20]
1.34 [0.14 ; 12.66 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 743, 2021 5.73 [0.29; 114.85]
DETERMINE, 2017 1.99 [0.09; 44.45]
3.44 [0.40 ; 29.74 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 3.02 [0.36; 25.23]
1.79 [0.30 ; 10.85 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 low not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.47 [0.02; 14.14]
DETERMINE, 2017 0.99 [0.03; 29.79]
0.69 [0.06 ; 7.58 ] CheckMate 743, 2021, DETERMINE, 2017 2 0% 1,153 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.18 [0.04; 0.85]
DETERMINE, 2017 1.50 [0.15; 14.48]
0.44 [0.06 ; 3.34 ] CheckMate 743, 2021, DETERMINE, 2017 2 56% 1,153 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 743, 2021 0.08 [0.00; 1.39]
DETERMINE, 2017 0.87 [0.25; 3.00]
0.37 [0.04 ; 3.57 ] CheckMate 743, 2021, DETERMINE, 2017 2 56% 1,153 low not evaluable Weight decreased TRAE (grade 3-4)detailed results DETERMINE, 2017 0.99 [0.09; 11.04]
0.99 [0.09 ; 11.04 ] DETERMINE, 2017 1 0% 569 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-07 00:43 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 139,222,223,221
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743